Other cardioprotective agents, including beta-blockers (BB), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs), have demonstrated effectiveness in reducing the risk of cardiotoxicity among cancer patients, as evidenced by various RCTs. The gene discussed is ACE; the disease is cancer.